Project Progress Report
VAS
Sr. No. CRF No. Age Sex
No. of headache days in
last 90 days
MIDAS
Pre-ATP Post-ATP Pre-ATP Post-ATP
Pre-ATP Post-ATP
25 061 43 F 8 3 50 9 60 6
26 063 25 F 10 3 47 5 45 4
27 064 40 M 9 2 43 4 33 4
28 066 25 F 8 3 37 4 66 7
29 067 40 F 7 2 34 4 35 3
30 068 50 M 8 3 30 6 45 8
31 069 36 F 9 3 29 6 90 12
32 070 44 F 9 LTF 45 LTF 90 LTF
33 076 26 M 7 3 38 10 30 10
34 078 42 M 8 3 44 12 60 12
35 080 18 F 8 4 50 11 60 8
36 085 36 F 9 5 55 30 65 15
37 082 36 M 10 6 46 19 90 12
38 086 35 F 9 7 39 22 75 10
39 088 20 F 8 5 45 23 48 8
40 089 35 M 7 On ATP 40 On ATP 75 On ATP
41 091 60 F 9 On ATP 58 On ATP 90 On ATP
42 093 20 F 8 On ATP 47 On ATP 50 On ATP
43 094 44 F 9 On ATP 57 On ATP 66 On ATP
44 096 62 M 8 On ATP 48 On ATP 45 On ATP
45 098 28 M 9 On ATP 52 On ATP 60 On ATP
46 099 24 F 7 On ATP 43 On ATP 35 On ATP
47 100 31 F 8 On ATP 47 On ATP 60 On ATP
48 102 40 F 8 On ATP 45 On ATP 45 On ATP
Randomized controlled clinical trial to evaluate prophylactic
28 properties of Ayu rv ed ic Treatment Protocol in
refractory and chronic migraine patients